Abstract-Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation that are required for hemostasis. However, aberrant activation of coagulation can lead to thrombosis. Thrombi can cause tissue ischemia, and fibrin degradation products and activated platelets can enhance inflammation. In addition, coagulation proteases activate cells by cleavage of PARs (protease-activated receptors), including PAR1 and PAR2. Direct oral anticoagulants have recently been developed to specifically inhibit the coagulation proteases FXa (factor Xa) and thrombin. Administration of these inhibitors to wild-type mice can be used to determine the roles of FXa and thrombin in different inflammatory diseases. These results can be compared with the phenotypes of mice with deficiencies of either Par1 (F2r) or Par2 (F2rl1). However, inhibition of coagulation proteases will have effects beyond reducing PAR signaling, and a deficiency of PARs will abolish signaling from all proteases that activate these receptors. We will summarize studies that examine the roles of coagulation proteases, particularly FXa and thrombin, and PARs in different mouse models of inflammatory disease. Targeting FXa and thrombin or PARs may reduce inflammatory diseases in humans.
T he primary function of the blood coagulation cascade is to prevent blood loss after vessel injury. This cascade is initiated by the TF (tissue factor)/FVIIa (factor VIIa) complex. FXa (factor Xa) and thrombin are components of the so-called common pathway. [1] [2] [3] Thrombin is the central protease of the blood coagulation cascade and has numerous roles, including cleavage of fibrinogen to fibrin and activation of platelets (Figure) . Aberrant activation of the blood coagulation system can contribute to the pathology of various diseases. Formation of thrombi within blood vessels leads to ischemia and inflammation. In addition, fibrin degradation products are released during the degradation of fibrin, that can enhance inflammation. For instance, the E1 fragment increases the recruitment of leukocytes to sites of injury by binding to VE-cadherin on endothelial cells and integrin αMβ2 on leukocytes. 4 In addition, macrophage activation is enhanced by binding to fibrin(ogen) via αMβ2. 5 Moreover, activated platelets can enhance inflammation by releasing inflammatory mediators and by promoting extravasation of leukocytes. 6 Finally, FXa and thrombin activate a variety of cell types, including endothelial cells, vascular smooth muscle cells, macrophages, fibroblasts, and cardiac myocytes, via PARs (protease-activated receptor; Figure) . There are 4 members of the PAR family (PAR1-4), and they are ubiquitously expressed. These receptors belong to the large family of G-protein-coupled receptors but are unique because they are activated by proteolytic cleavage that exposes a tethered ligand. Thrombin activates PAR1, PAR3, and PAR4, whereas FXa primarily activates PAR2. [7] [8] [9] [10] Importantly, other proteases also activate PAR1 and PAR2. For example, APC (activated protein C) and matrix metalloproteases activate PAR1, [11] [12] [13] whereas trypsins, tryptase, FVIIa, and matriptase activate PAR2. [14] [15] [16] In addition, PAR1 and PAR2 can form heterodimers 17, 18 Interestingly, human platelets express PAR1 and PAR4, whereas mouse platelets express a PAR3/PAR4 complex. [19] [20] [21] This means that any phenotype observed in Par1 −/− mice cannot be because of an attenuation of platelet activation. Furthermore, there may be differences in PAR signaling in mice and humans.
A number of anticoagulants, such as vitamin K antagonists and various forms of heparins, are used to prevent and treat venous thrombosis and prevent stroke associated with atrial fibrillation. 22 Direct oral anticoagulants (DOACs), which are also known as non-vitamin K antagonist oral anticoagulants, are a relatively new class of anticoagulants that specifically inhibit FXa and thrombin. 23, 24 There are several FXa inhibitors (apixaban, betrixaban, edoxaban, and rivaroxaban) but only 1 approved thrombin inhibitor called dabigatran etexilate, which is a prodrug that is metabolized to dabigatran. 24 Various DOACs have been used to study the roles of FXa and thrombin in various mouse models of disease, but rivaroxaban and dabigatran are the most popular. As expected, therapeutic doses of these inhibitors reduce thrombosis in mice. [25] [26] [27] We will not discuss studies that investigated the antithrombotic activities of these drugs. One would expect different effects of rivaroxaban versus dabigatran on PAR signaling. For instance, inhibiting FXa would be expected to primarily inhibit PAR2 signaling, whereas inhibiting thrombin would primarily inhibit PAR1 signaling, as well as PAR3 and PAR4 signaling ( Figure) . Additionally, Par2 −/− and Par1 −/− mice can be used to compare and contrast the effects seen in wild-type mice with pharmacological inhibition of either FXa or thrombin, respectively. However, inhibition of proteases will have effects beyond PAR signaling, and a Par deficiency will abolish signaling from multiple proteases. In addition, studies with Par1 −/− or Par2 −/− mice do not provide any information on the protease(s) that are activating the PARs in a given disease or the effector cells that are expressing the PARs. Recently, transgenic mouse lines containing floxed Par1 and Par2 genes have been generated (J. Palumbo, unpublished data, 2018; E. Camerer, unpublished data, 2018), and these mice are being used to determine the role of PAR1 and PAR2 in different cell types in multiple diseases. Similarly, transgenic mice have been made that express mutant forms of PAR1 and PAR2 that cannot be activated by particular proteases. For instance, PAR1
R41Q cannot be activated by either thrombin or APC, whereas PAR1
R46Q cannot be activated by APC. 28 Another mouse line was generated that expresses PAR2
G37I that is resistant to activation by FXa. 29 These mice will be useful to determine the role of different proteases in the activation of PARs in various diseases.
In this review, we summarize the effects of inhibiting different coagulation proteases, particularly FXa and thrombin, in wild-type mice and compare these results with the phenotypes of Par1-and Par2-deficient mice in various mouse models of inflammatory disease. We will not discuss studies on cancer because this topic has been reviewed previously.
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Doses of Rivaroxaban and Dabigatran Etexilate Used in Mouse Studies
The therapeutic dose of rivaroxaban used in humans is between 0.13 and 0.27 mg/kg (based on a patient weight of 75 kg), which gives peak plasma concentrations of 122 to 250 ng/mL. 34, 35 Dabigatran etexilate has a low bioavailability, and, therefore, it requires a high therapeutic dose in humans between 2 and 4 mg/kg, which gives peak plasma concentrations of 121.6 to 172.9 ng/mL (dose between 2.9 and 4.0 mg/kg). [36] [37] [38] When using DOACs in mice, one has to consider the biological differences between humans and mice, including the faster metabolism of mice, the shorter half-life in mice, and the fact that the drugs were developed to inhibit the human coagulation proteases. 39 Therefore, higher doses of these drugs are needed for mice.
Rivaroxaban and dabigatran etexilate as well as other DOACs, such as edoxaban, are administrated to mice via either chow, oral gavage, or intravenous injection (Tables 1 and  2 ). Most studies report the dose in terms of milligrams per gram of chow. Only some studies report the plasma levels of the drug and present data from plasma-based functional assays that indicate the level of anticoagulation (Tables 1 and  2 ). Plasma levels of rivaroxaban and dabigatran can be measured using an anti-FXa-based assay and chromatography mass spectrometry, respectively. 40, 41 There is a wide range of doses of rivaroxaban that have been used in mice (0.006-1.2 mg/g chow; Table 1 ). We found that a rivaroxaban dose of 1.2 mg per chow produced a plasma level of 150 to 260 ng/mL in apoE −/− mice fed a Western diet (40.5% fat and 0.25% cholesterol; J. Posma and H. Spronk, unpublished data, 2018) . Rivaroxaban induces a linear, concentration-dependent prolongation of the prothrombin time, making it a suitable test to measure the level of anticoagulation with rivaroxaban. 34 One study used 3 different doses of rivaroxaban (0.01, 0.2, and 0.4 mg/g chow) and found a significant increase in prothrombin time with the 2 higher doses. 45 doses have been used in different mouse studies (Table 2) . Interestingly, the level of absorption of dabigatran etexilate is affected by the type of diet. 46, 48 The activated partial thromboplastin time correlates with the level of dabigatran at therapeutic plasma levels and is used to monitor the anticoagulation of this DOAC. However, the activated partial thromboplastin time loses sensitivity at supratherapeutic levels of dabigatran (>200 ng/mL). 54, 55 Thrombin time is sensitive to the levels of dabigatran etexilate at plasma levels <60ng/mL, but no correlation is observed at higher levels. One study evaluated 3 doses of dabigatran (5, 10, and 15 mg/g chow) in mice and found that the 10-and 15-mg/g doses significantly increased the activated partial thromboplastin time. 45 Another study found that a dose of 10 mg/g of dabigatran etexilate increased the thrombin time from 30 to 93 seconds. 48 An oral dose of 100 mg/kg body weight of dabigatran etexilate did not cause any bleeding complication. 57 This study showed that dabigatran is rapidly cleared in mice with a half-life of 1.25 hours. However, sickle cell mice bled spontaneously when dabigatran etexilate was given by chow at a dose of 15 mg/g chow, and wild-type mice bled spontaneously when they received a dose of 500 mg/kg of body weight by oral gavage (E. Sparkenbaugh and R. Pawlinski, unpublished data, 2018).
Atherosclerosis
High levels of TF expression and procoagulant activity are present in human atherosclerotic plaques. [58] [59] [60] TF expression has also been observed in a rabbit model of atherosclerosis. 61 In addition, levels of TF expression are increased with progression of human lesions. 62 
ApoE
−/− and Ldlr −/− mice are the most common models used to study atherosclerosis in mice. 63 Humans carry the majority of their lipoproteins in the LDL (low-density lipoprotein) subfraction, whereas mice transport their lipoproteins via high-density lipoprotein. Feeding apoE −/− and Ldlr −/− a Western diet, which is classically regarded as 42% fat and 0.2% cholesterol, results in high levels of LDL that resembles distinct genetic disorders in humans (familial dysbetalipoproteinemia and hypercholesterolemia). However, mice fed a Western diet also have abnormally high chylomicrons and LDL compared with humans. ApoE −/− mice develop spontaneous atherosclerotic lesions on regular chow, but atherosclerosis is markedly accelerated by feeding a Western diet. 64, 65 In contrast, most studies with Ldlr −/− mice use a Western diet because there is limited atherosclerosis on regular chow with young mice. Atherosclerosis is normally measured in the aortic sinus, ascending aorta, and innominate artery. Addition of a cuff around the carotid artery creates vascular shear stress and vascular injury that accelerates atherosclerosis. Deletion of the apoE gene interferes with various processes, including macrophage and adipose tissue biology, whereas deletion of the Ldlr gene primarily affects LDL clearance from the liver. 66, 67 When interpreting mouse data, one also has to consider the differences between mice and humans, including differences in lesion distribution, medial layer size, and lipoprotein transport. 63, 68 Both apoE −/− and Ldlr −/− mice fed a Western diet have a prothrombotic state, as measured by increased levels of plasma thrombin-antithrombin complex.
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Effect of Deficiencies of Procoagulant or Anticoagulant Proteins on Atherosclerosis in Mice
Components of the coagulation system have been implicated in the development of atherosclerosis. 69 Increased atherosclerotic lesion development was observed in apoE −/− mice expressing the hypercoagulable Factor V Leiden variant, which is likely because of an increased capacity for thrombin generation. 70 Similarly, a 50% reduction in TF pathway inhibitor-the endogenous inhibitor of TF-increased the development of lesions in apoE −/− mice fed regular chow. 71 Conversely, a 50% reduction of TF did not alter atherosclerotic lesion development in apoE −/− mice fed regular chow. 72 Similarly, no difference in atherosclerotic lesion development was observed in Ldlr −/− mice reconstituted with bone marrow expressing low levels of TF on a Western diet. 72 Genetic studies have investigated the role of thrombin on the development of atherosclerosis. Interestingly, apoE −/− mice with 50% levels of prothrombin had reduced lesion burden on regular chow. 50 The role for fibrinogen-the major physiological substrate of thrombin-in atherosclerosis is model dependent. In addition, it should be noted that fib −/− mice are difficult to breed. In the apoE −/− model, fibrinogen deficiency did not alter atherosclerotic lesion development in mice on normal chow. 73 However, in a transgenic mouse model expressing human apo(a), deletion of fibrinogen significantly reduced lesion development in mice fed a Western diet because of reduced binding of apo(a) to fibrin(ogen) in the vessel wall. 74 Finally, fibrinogen deficiency increased plaque development in Ldlr −/− mice with a deficiency in apobec1. 75 Taken together, these genetic studies suggest that thrombin contributes to atherosclerosis in mouse models.
Effect of Thrombin Inhibition on Atherosclerosis in Mice
The first study on the effect of the orally available thrombin inhibitor melagatran was performed in 2006. 76 Melagatran decreased progression of advanced lesions in apoE −/− mice on chow. 76 In addition, melagatran decreased inflammation and macrophages in the lesion and increased collagen and fibrous cap thickness, which is suggestive of a stable plaque phenotype. Similarly, dabigatran etexilate reduced atherosclerosis in apoE −/− mice on chow. 49 Moreover, 3 studies demonstrated that dabigatran etexilate (5.6-10 mg/g chow) reduced atherosclerosis in apoE −/− mice fed a Western diet. [46] [47] [48] These studies also showed that thrombin inhibition reduced inflammation, macrophage accumulation, and necrotic core volume while increasing fibrous cap thickness and improving endothelial function. In the cuff model, dabigatran etexilate reduced atherosclerosis in Western diet-fed apoE −/− mice expressing a mutant version of thrombomodulin with reduced anticoagulant activity. 50 In contrast, the thrombin inhibitor bivalirudin did not attenuate atherosclerosis. 77 However, bivalirudin has a short half-life and was administered daily via subcutaneous injection. Taken together, the majority of studies demonstrated that inhibition of thrombin decreased atherosclerosis and inflammatory mediators, such as IL-6 (interleukin-6), MCP-1 (monocyte chemoattractant protein 1), IFN-γ (interferon gamma), and TNF-α (tumor necrosis factor-α), in apoE −/− mice.
Effect of FXa Inhibition on Atherosclerosis in Mice
Low-dose rivaroxaban attenuated the development of atherosclerosis and inflammation in the aorta of 8-week-old male apoE −/− mice fed a Western diet for 20 weeks. 78 Interestingly, low-dose rivaroxaban (0.006 and 0.031 mg/g chow) did not induce plaque regression in female apoE −/− mice fed regular chow for 26 weeks and then given rivaroxaban for an additional 26 weeks. 42, 78 However, both doses of rivaroxaban reduced the expression of inflammatory mediators, such as TNF-α and IL-6. 42 Additionally, the 0.031 mg/g dose of rivaroxaban stabilized the plaque phenotype as reflected by a thicker fibrous cap, smaller necrotic cores, and more collagen. 42 We found that high-dose rivaroxaban (1.2 mg/g diet) reduced the development of atherosclerosis in 8-week-old female Ldlr −/− mice fed a Western diet for 14 weeks in the cuff model (J. Posma and H. Spronk, unpublished data, 2018). Additionally, we examined the effect a high-dose rivaroxaban (1.2 mg/g chow) on preexisting plaques by feeding female apoE −/− mice Western diet for 14 weeks and then administering rivaroxaban for 6 weeks in the cuff model. Rivaroxaban promoted regression of preexisting plaques (J. Posma and H. Spronk, unpublished data, 2018). These differences are likely because of the use of a different dose of rivaroxaban (1.2 versus 0.03 mg/g chow) with the higher dose more typical for studies with rivaroxaban.
Effect of Par1 Deficiency or Par1 Inhibition on Atherosclerosis in Mice
PAR1 expression is increased in human and mouse atherosclerotic lesions suggesting that it may play a role in atherosclerosis. 79 There are several studies that have investigated the role of PAR1 in atherosclerosis in the apoE −/− and Ldlr −/− models (Table 3) . However, the data are inconsistent between the 2 models. In the apoE −/− mouse model with Western diet Par1 deficiency reduced atherosclerosis, whereas Par1 deficiency had no effect in the Ldlr −/− model fed Western diet. [79] [80] [81] Inhibition of PAR1 with the cell penetrating PAR1 pepducin PZ-128 also reduced atherosclerosis, macrophage content of plaques, and inflammation in apoE −/− mice fed a Western diet. 77 However, one must be cautious with the interpretation of this data because PZ-128 also inhibits signaling from a PAR1/PAR2 heterodimer. 82 In vitro studies indicated that the thrombin-PAR1
pathway inhibits cholesterol efflux in macrophages and vascular smooth muscle cells, and contributes to leukocyte migration into lesions. 80 19 Platelets have been shown to contribute to atherosclerosis in mice. 88 An early study found that Par4 deficiency did not affect atherosclerosis in apoE −/− mice fed a Western diet. 89 In contrast, we observed a significant reduction in atherosclerosis in male Ldlr −/− mice lacking Par4 fed a Western diet for 12 weeks (A.P. Owens 3rd and N. Mackman, unpublished data, 2018) . This suggests that the contribution of the thrombin/PAR4 pathway is relatively mild and can only be detected in the Ldlr −/− model.
Effect of PAR2 Deficiency on Atherosclerosis in Mice
PAR2 expression is increased in human atherosclerotic plaques suggesting that it may contribute to plaque progression. 79 Several studies have determined the effect of Par2 deficiency on atherosclerosis in mice (Table 4) . Par 2 deficiency was associated with reduced atherosclerosis, reduced inflammation, and increased plaque stability in apoE −/− mice fed a Western diet. 90 This phenotype was confirmed and extended by a later study. 43 Bone marrow transplantation experiments indicated that Par2 on hematopoietic cells but not nonhematopoietic cells drove atherosclerosis. 43 Furthermore, in vitro studies showed that activation of PAR2 on macrophages increased inflammation. Additionally, the PAR2 pepducin inhibitor PZ-235 showed no effects on lesion development in apoE −/− mice fed a Western diet. 77 We found that a deficiency of Par2 also attenuated atherosclerosis in Ldlr −/− mice fed a Western diet. 79 Mice lacking Par2 had decreased expression of the chemokines CCL2 and CXCL1 in the circulation. 79 However, in contrast to the studies with the apoE −/− mice, bone marrow transplantation experiments indicated that Par2 on nonhematopoietic cells but not hematopoietic cells drove atherosclerosis in this model. In vitro studies indicated that activation of PAR2 on vascular smooth muscle cells induced Ccl2 and Cxcl1 expression and enhanced monocyte migration. 79 It is surprising that there are cell type differences in the role of PAR2 in the apoE −/− and Ldlr −/− mice. Additional studies are needed to compare the phenotypes of wild-type mice treated with rivaroxaban and Par2 −/− mice in the 2 models.
Myocardial Infarction
Myocardial infarction is a leading cause of morbidity and mortality. The most commonly used models of myocardial infarction in mice are either permanent ligation of the left anterior descending (LAD) artery or temporary ligation of the LAD followed by reperfusion (ischemia-reperfusion model [I/R]). 40, 98 I/R can be either an open-chest model (I/R-O) similar to LAD, where the opening of the chest precedes I/R on the same day, 98 or in a closed-chest model where the ligature is placed around the LAD without tying and mice allowed to recover for 5 to 7 days before ligation (I/R-C). 99 In the I/R-O model, the surgery contributes to the inflammatory response, whereas in the I/R-C model, most of the surgical inflammation has resolved at days 5 to 7. 99 The I/R models provide information on the role of different pathways involved in reperfusion injury.
Effect of Inhibition of Coagulation on Myocardial Infarction in Mice
We found that inhibiting the TF/FVIIa complex in mice with active site-inhibited FVIIa reduced infarct size in an I/R-C model that consisted of 60 minutes of ischemia and 2 hours of reperfusion. 100 This was associated with reduced leukocyte infiltration and decreased gene expression of inflammatory mediators, such as IL-6, intercellular adhesion molecule-1, and IL-1β. 100 Similarly, the thrombin inhibitor hirudin also reduced infarct size in the I/R-O model that consisted of 30 minutes of ischemia and 2 hours of reperfusion. 83 We determined the effect of rivaroxaban on infarct size in an I/R-C model by administering 2 doses of rivaroxaban via intravenous injection (1.6 mg/kg) 15 minutes after ischemia and 5 minutes after reperfusion. Rivaroxaban significantly reduced infarct size after 24 hours (J. Posma and H. Spronk, unpublished data, 2018).
In the LAD permanent ligation model, administration of rivaroxaban (0.5 mg/g chow) immediately after cardiac injury did not alter infarct size but reduced remodeling of the heart and preserved ejection fraction after 3 days and beyond compared with the placebo group. 40 Interestingly, no protection was observed when rivaroxaban treatment was started 3 days post-ligation. This suggests that FXa inhibition affects the acute inflammatory phase in this model. However, rivaroxaban treatment did not alter inflammatory mediators 2 days after ligation. 40 In this study, an open-chest model was used that promotes inflammation, which might have masked the effects of FXa inhibition on inflammation.
These studies indicate that coagulation proteases contribute to inflammation and infarct size after cardiac I/R injury. The protective effects seen with inhibition of coagulation after cardiac injury may be because of a combination of reduced fibrin deposition, activation of PARs and other downstream effects, such as generation of fibrin degradation products and platelet activation.
Effect of Par1 Deficiency on Myocardial Infarction in Mice
We found that Par1 deficiency did not affect infarct size but reduced remodeling 2 weeks post-infarction in an I/R-O model ( Table 3) . 83 The lack of effect of PAR1 on infarct size may be because it mediates both pathological and protective pathways via APC. Indeed, exogenous APC was shown to reduce infarct size after I/R injury, and this effect was abolished in Par1 −/− mice. 101, 102 As stated above, Par1 deficiency does not affect platelet activation in mice. However, Par4 deficiency reduced infarct size in an I/R-O model. 103 These studies suggest that some of the beneficial effects of thrombin inhibition might be because of a reduction in PAR4 signaling.
Effect of Par2 Deficiency on Myocardial Infarction in Mice
We found that Par2 deficiency attenuated infarct size in an I/R-O model consisting of 30 minutes of ischemia and 2 hours of reperfusion (Table 4) . 91 In addition, hearts of Par2 −/− mice had reduced levels of inflammatory mediators, such as IL-1β and TNF-α, and decreased remodeling compared with hearts from wild-type mice. 91 In the LAD permanent ligation model, Par2 −/− mice had reduced remodeling and preserved ejection fraction after 28 days. 104 This result is similar to the protective effects of rivaroxaban in the wild-type mice. 40 Indeed, rivaroxaban did not provide any protection to Par2 −/− mice in the LAD permanent ligation model. 40 However, one must be cautious in interpreting these results because FXa and PAR2 may play roles in parallel pathways that contribute to cardiac remodeling after myocardial infarction. For instance, administration of rivaroxaban would reduce levels of the fibrin degradation fragment E1, which has been shown to exacerbate I/R injury 4 ( Figure) . Additionally, activation of PAR2 by other protease would be abolished in Par2 −/− mice.
Diet-Induced Obesity
Obesity is a global healthcare crisis with an estimated 34% of adults in the United States classified as obese. 105 Obesity leads to chronic activation of the coagulation cascade and is a risk factor for the development of metabolic syndrome. 84, 106 High levels of TF are expressed in adipose tissue, and there is abundant fibrin deposition in adipose tissue. 51, 107, 108 The role of the coagulation cascade and PARs in diet-induced obesity has been studied using different mouse models that are associated with body weight gain, inflammation, macrophage recruitment to the adipose tissue, and insulin resistance.
Two studies from the Samad group found that Par2 −/− mice and mice expressing a mutant form of TF that lacks the cytoplasmic domain had reduced weight gain in a diet-induced obesity model. 92, 93 It was proposed that hematopoietic cell TF-PAR2 signaling increases adipose inflammation, hepatic inflammation, hepatic macrophage recruitment, and steatosis, whereas nonhematopoietic cell TF-FVIIa-PAR2 signaling drives obesity. We found that mice expressing low levels of TF exhibited significantly less body weight gain when fed a high-fat diet (HFD; 45% kcal fat) for 16 weeks compared with controls (Y. Hisada and N. Mackman, unpublished data, 2018). Notably, adipocyte size was increased in epididymal and subcutaneous fat in wild-type controls but not in low TF mice (Y. Hisada and N. Mackman, unpublished data, 2018). Similarly, low levels of TF expression in hematopoietic cells were also associated with significantly less body weight gain in Ldlr −/− mice fed a Western diet compared with controls. 106 Administration of dabigatran etexilate to C57BL/6J mice reduced body weight gain when fed an HFD. 51, 52 Dabigatran also suppressed the progression of sequelae in mice with establish obesity. 51 In contrast, a deficiency of Par1 did not affect diet-induced body weight gain. 51, 84 This initiated a search for the effector molecule(s) downstream of thrombin that drove obesity. One obvious candidate was fibrinogen. A previous study found that a sequence in the fibrinogen γ-chain (390-396) binds to macrophages via αMβ2 and that mutation of this sequence abolished binding. 109 Strikingly, mice expressing this mutant fibrinogen Fibγ 390-396A were protected from diet-induced body weight gain in a similar way to thrombin-inhibited wild-type mice. 51 Similar to the results we observed with low TF mice, the size of adipocytes was not increased in Fibγ 390-396A mice fed an HFD. 51 In addition, Fibγ 390-396A mice had reduced numbers of macrophages in the adipose tissue. 51 These results suggest that thrombin drives diet-induced obesity via fibrindependent inflammation in the adipose.
Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease is the liver manifestation of metabolic syndrome and is estimated to affect ≈25% of the Western population. 110 Mice fed a Western diet develop hepatic inflammation and fatty livers that is mainly because of the accumulation of triglycerides. This is referred to as steatosis. We found that low TF fed a Western diet for 16 weeks did not develop steatosis (Y. Hisada and N. Mackman, unpublished data, 2018). Similarly, low levels of TF expression in hematopoietic cells reduced hepatic steatosis in Ldlr −/− mice fed a Western diet. 84 Par1 deficiency also reduced hepatic inflammation and steatosis in C57BL/6J mice fed a Western diet for 3 months. 84 Finally, Fibγ 390-396A mice had reduced hepatic inflammation and steatosis when fed a Western diet compared with controls. 51 These results indicate that TF-thrombin-PAR1 and TF-thrombin-fibrin pathways contribute to hepatic inflammation and steatosis in mice fed a Western diet.
Diabetic Nephropathy
Diabetic nephropathy is the most common cause of endstage renal disease in the United States. 111 In a mouse model of diabetic nephropathy, FXa inhibition by edoxaban attenuated progression of the disease. 94 This was associated with decreased expression of proinflammatory genes, such as TNF-α, and profibrotic genes, such as ΤGF-β. Interestingly, Par2 deficiency gave a similar phenotype, and edoxaban did not provide any additional protection to Par2 −/− mice. 94 The authors speculated that targeting FXa or PAR2 may reduce diabetic nephropathy in humans.
Sickle Cell Disease
A substitution of glutamic acid in normal hemoglobin for valine causes sickle cell disease. The mutant hemoglobin polymerizes and aggregates of hemoglobin tetramers leads to the formation of sickle red blood cells. Patients with sickle cell disease exhibit vaso-occlusion within postcapillary venules and have systemic inflammation and activation of coagulation. 112 The 2 most common mouse models of sickle cell disease (Berkley [BERK] and Townes) have the mouse hemoglobin genes replaced with their human counterparts. 113, 114 BERK and Townes mice have severe anemia, systemic inflammation, and activation of coagulation. 115 The role of the clotting cascade in sickle cell mice has been analyzed using genetic and pharmacological approaches. Inhibition of TF reduced both coagulation and the inflammatory mediator IL-6 in both BERK and Townes mice. 115 Moreover, reducing TF expression in nonhematopoietic cells to ≈1% in BERK mice reduced plasma IL-6, cardiac hypertrophy, and infiltration of neutrophils into the lungs but not activation of coagulation. 116 Deletion of TF in endothelial cells also reduced plasma IL-6 but not activation of coagulation. 45 Similarly, reducing circulating prothrombin to ≈10% of wildtype levels using an antisense oligonucleotide decreased early mortality in BERK mice. 117 In addition, a genetic reduction of prothrombin to ≈10% of wild-type levels in BERK mice reduced inflammation, endothelial dysfunction, and endorgan damage in the kidney, liver, and lung. 117 Interestingly, short-term FXa inhibition with rivaroxaban, but not short-term thrombin inhibition with dabigatran, significantly reduced IL-6 plasma levels in sickle cell mice. 45 Similarly, Par2 −/− mice but not Par1 −/− mice with sickle cell bone marrow had reduced levels of plasma IL-6. 45 These results indicate that TF, FXa, and thrombin contribute to the activation of coagulation in sickle cell mice. In contrast, inflammation and end-organ dysfunction are more complex and seem to be driven by multiple pathways that include endothelial cell TF expression that activates PAR2 and also thrombin-dependent pathways. The different phenotypes observed in sickle cell mice may be because of the use of genetic versus pharmacological approaches and short-versus long-term studies.
Viral Infections
The blood coagulation cascade is activated in response to viral infection and can lead to disseminated intravascular coagulation. 118 Inhibition of the TF/FVIIa complex reduced inflammation and mortality in a primate model of Ebola hemorrhagic fever. 119 The roles of PAR1 and PAR2 in mouse models of viral infections are controversial. 118 
Coxsackievirus B3
We found that inhibition of either TF with an antibody or thrombin with dabigatran etexilate increased viral load and January 2019 myocarditis after infection of mice with coxsackievirus B3 (CVB3). 53 Similarly, Par1 −/− mice exhibited increased CVB3-induced myocarditis (Table 3) . TLR3 (Toll-like receptor 3) is one of the main receptors in the innate immune system that detects single-stranded RNA viruses, such as CVB3. TLR3 can be activated by the double-stranded RNA mimetic poly I:C. Importantly, we found that activation of PAR1 enhanced poly I:C induction of IFN-β expression in murine cardiac fibroblasts, suggesting that PAR1 contributes to the innate immune response to single-stranded RNA viral infection. 53 In complete contrast to the results with Par1 −/− mice, Par2 −/− mice were protected against CVB3-induced myocarditis. 95 We also found that administration of rivaroxaban (0.5 mg/g chow) to wild-type mice decreased CVB3-induced myocarditis (S. Antoniak and N. Mackman, unpublished data, 2018). Interestingly, murine cardiac fibroblasts lacking PAR2 had higher levels of IFN-β expression after stimulation with poly I:C compared with wild-type cells, suggesting that PAR2 negatively regulates TLR3-dependent expression of IFN-β. 95 Similarly, PAR2 inhibited TLR3-dependent expression of IFN-β in human epithelial cells. 96 These studies suggest that TLR3-dependent activation of antiviral pathways is positively and negatively regulated by PAR1 and PAR2, respectively.
Influenza A Virus
Influenza A virus (IAV) is a single-stranded RNA virus. Khoufache et al 86 found that Par1 deficiency decreased inflammation and increased survival of mice infected with a mouse adapted H1N1 strain of IAV (Table 3 ). In contrast, we found that Par1 −/− mice exhibited a decrease in the innate immune response and increase in virus genomes after IAV infection. 53 We have also observed increased mortality in Par1 −/− mice compared with wild-type controls after IAV infection (S. Antoniak and N. Mackman, unpublished data, 2018). These variable results may be because of the use of a different dose of virus. Similarly, the results with Par2 −/− are not consistent. Khoufache et al 97 observed that Par2 −/− mice had increased inflammation and decreased survival after IAV infection. In contrast, the Vogel group found that Par2 −/− mice exhibited increased survival compared with controls after IAV infection. 96 Similarly, administration of rivaroxaban (0.5 mg/g chow) to wild-type mice increased survival after IAV infection compared with controls (S. Antoniak and N. Mackman, unpublished data, 2018). Further studies are needed to determine the roles of coagulation proteases and PARs in IAV infection.
Other Viruses
PAR1 inhibition protected mice against respiratory syncytial virus and human metapneumovirus infection. 120 Similarly, thrombin inhibition with argatroban reduced the pathogenicity of the infection with no additional effect to PAR1 inhibition. In vitro studies with human A549 cells showed that PAR1 inhibition reduced the replication of respiratory syncytial virus and human metapneumovirus infection. 120 Further studies are needed to determine the roles of coagulation proteases and PARs in different viral infections.
Sepsis/Endotoxemia
Sepsis is induced by a systemic infection and activates the coagulation system. Endotoxemia is related to sepsis and is caused by endotoxins, most commonly bacterial lipopolysaccharide, in the blood. Lipopolysaccharide induces TF expression in monocytes. 121 Administration of lipopolysaccharide to mice leads to a rapid activation of coagulation. We found that mice expressing low levels of TF had less activation of coagulation and prolonged survival compared with controls in an endotoxemia model. 122 In a subsequent publication, we demonstrated endotoxemia-induced activation of coagulation was initiated by both hematopoietic and nonhematopoietic sources of TF. 123 Furthermore, inhibition of thrombin with hirudin prolonged survival but did not reduce inflammation. We also found that Par1-and Par2-deficient mice were not protected against endotoxemia. 122 An independent study also showed that a deficiency of Par1, Par2, or Par4 did not affect inflammation or survival in an endotoxemia model that used different doses of lipopolysaccharide and both sexes. 124 In contrast to these 2 studies, 1 study reported protection of Par1-deficient mice in an endotoxemia model. 125 More recently, it was shown that mice expressing PAR1
R41Q that cannot be activated by thrombin were not protected in an E coli-induced pneumonia model. 28 These studies indicate a role for TF and thrombin in the activation of coagulation in endotoxemia, but the role of PARs in the inflammatory response in this model is controversial.
Idiopathic Pulmonary Fibrosis
The coagulation cascade plays a critical role in hemostasis in the lung but also contributes to fibroproliferative lung diseases, such as idiopathic pulmonary fibrosis. The ACE-IPF trial (Antioagulant Effectiveness in Idiopathic Fibrosis) investigated the effect of the anticoagulant warfarin in idiopathic pulmonary fibrosis but was stopped early because of excess risk of mortality. 126 Bleomycin induces lung injury and fibrosis in mice and is an established model of human pulmonary fibrosis. We found that bleomycin increased TF expression in the lungs of mice. 127 One study showed that administration of an FXa inhibitor ZK80734 to mice reduced bleomycininduced lung injury in mice. 128 However, it is notable that 3 of 6 mice that received saline and ZK80734 and 3 of 9 mice that received bleomycin and ZK80734 were euthanized because of intraperitoneal hemorrhage after administration of the drug. PAR1 is highly expressed in cells associated with fibrotic foci in idiopathic pulmonary fibrosis suggesting that it may contribute to fibrosis. 129 Indeed, Par1 −/− mice were protected from bleomycin-induced lung inflammation. 87 In vitro studies showed that FXa activated PAR1 on human adult lung fibroblasts.
128 PAR1 signaling leads to activation of TGF-β1, which is a key fibrotic mediator in many fibrotic conditions.
Conclusions
Activation of the blood coagulation leads to the generation of multiple coagulation proteases, fibrin deposition, proinflammatory fibrin degradation products, platelet activation, and PAR signaling (Figure) . In atherosclerosis, inhibition of either FXa or thrombin reduces inflammation and lesion development. Similarly, a deficiency of Par2 reduces inflammation and atherosclerosis, but PAR2 seems to play different roles in the apoE −/− and Ldlr −/− models. Par1 deficiency reduces atherosclerosis in the apoE −/− model, and this may be because of reduced cholesterol influx and monocyte migration into lesions. However, Par1 deficiency had no effect in atherosclerosis in the Ldlr −/− model. In cardiac I/R injury, inhibition of either TF/FVIIa, FXa, or thrombin reduces inflammation and infarct size. Similarly, Par2 −/− mice but not Par1 −/− mice had reduced infarcts compared with controls. In diet-induced obesity mouse models, the TF/FVIIa-thrombin-fibrin pathway and PAR2-dependent pathways drive inflammation in adipose tissue. In a mouse model of sickle cell disease, the TF/ FVIIa-FXa-PAR2 and TF-thrombin-PAR1 pathways drive inflammation and end-organ damage. The roles of PARs in viral infections are controversial. TLR3-dependent antiviral responses seem to be positively and negatively regulated by PAR1 and PAR2, respectively.
Further studies are needed with mice that express either mutant forms of the PARs or with cell type-specific deletion of PARs to elucidate how coagulation protease-PAR pathways contribute to different diseases.
